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ABSTRACT
Objective: To assess the role of rational drug use and laboratory services in preventing
the emergence of multiple antibiotic resistant Staphylococcus aureus in developing
countries
Data source: Literature search on compact disk-read only memory (CD-ROM) Medline
and Internet using the key words: Staphylococcus and antibiotic resistance. A few articles
were manually reviewed.
Study selection: Relevant studies or articles on antibiotic resistance with special reference
to Eastern Africa, region are included in the review.
Data extraction: From individual studies or articles.
Data synthesis: Evidence for the spread of S. aureus multiple antibiotic resistance is
synchronized under the headings: Introduction, current situation, antibiotic resistance
control strategies, are outlined.
Conclusion: There is need for concerted efforts between different groups to monitor
changes in the epidemiology and antibiotic resistance of S. aureus.Strategies aimed at
preventing transmission of resistant strains are remarkably effective when strictly
enforced. Necessary attention should be given on the subject so that meaningful control
measures preventing the expansion of antimicrobial resistance can be formulated,
thereby ensuring the future successful treatment of Staphylococcal infections.
INTRODUCTION
Staphylococcal infections continue to pose
important clinical problems. S. aureus is one of the
major causes of community-acquired and hospital-
acquired infections(2-4). Its main habitats are the nasal
membranes and skin of warm blooded animals, in
which it causes a wide range of infections from mild,
such as skin infections and food poisoning, to life
threatening, such as pneumonia, sepsis, osteomyelitis
and infectious endocarditis(5). Several antibiotics have
been used in combination as empiric antimicrobial
therapy for some of these infections, especially
aminoglycosides, penicillins, cephalosporins and
vancomycin as a consequence of the constantly changing
antimicrobial susceptibility patterns(6-8). Antibiotic
resistance among the Staphylococci has rendered therapy
of these infections a therapeutic challenge. Although
antibiotic resistance is a worldwide problem, developing
countries face special difficulties because alternative
and effective therapeutic options are either unavailable
or unaffordable(9). Effective action to prevent the
spread of resistance will not only ameliorate a major
problem but also demonstrate that different groups can
work together on difficult issues.
The discovery of penicillin in 1929 by Fleming,
and its therapeutic efficacy heralded the development
of many successful antimicrobial agents(10,11). Most
of the antimicrobial agents were discovered as
actinomycete products by the late 1950s. In addition
to the screening efforts, chemical modifications of
penicillins, cephalosporins and aminoglycosides began
in 1960s resulting in the synthesis of many useful
derivatives. The decade of the 1980s was marked by
acceleration in the development of new antimicrobial
compounds. The early part of 1980s was dominated by
introduction of multiple new beta-lactams, extended
spectrum penicillins and third generation cephalosporins
while the later part saw the introduction of
carbapenem(12).
ANTIMICROBIAL RESISTANT S. AUREUS: THE
CURRENT SITUATION
There has been much interest in the media,
national and international in the potential for the
development of "super bugs", by which is usually
meant pathogenic bacteria resistant o all available
antibi tics. We have witnessed a recent burst of
methicillin or multiple resistant S phylococcus aureus
(MRSA), vancomycin resistant S. aureus (VRSA) and
other bacteria in patients and the environment(2,3,8,13).
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This shows that the battle against bacteria is never
ending. Accurate determination of the magnitude of
MRSA requires detection of mecA gene, which encodes
for resistance to methicillin. Drugs of choice in patients
due to MRSA are glycopeptide agents such as
vancomycin and teichoplanin(14). Vancomycin was the
only antibiotic effective against it, but, in 1997,
vancomycin resistant S. aureus  was also isolated(15).
Vancomycin resistant S. aureus is the pathogen of
greatest concern.
Another compounding factor is the treatment of
S. aureus i  the frequency of resistance to both the older
and newer, third generation cephalosporins and other
commonly used antibiotics(3,13). The resistance of S.
aureus to antibiotics has led to the use of multiple drugs
on a routine basis as a consequence of the constantly
changing antimicrobial susceptibility pattern that are
characteristic of the targeted bacteria. A major drawback
is the newly recommended drugs are not readily
available in the most developing countries, and if
available are more expensive than those previously
used(9,16-18).
Antimicrobial susceptibility testing should include
antibiotics from several groups and having different
modes of action. Resistant isolates hould further be
studied for their genetic mechanisms of resistance by
means of molecular characterization. Bacteria posses a
remarkable number of ways to become resistant o
antibiotics, which can either be acquired or innate(19-
21). These include genetic mutation which alter binding
sites, production of enzymes that destroy or inactivate
antimicrobials, changing to other metabolic systems not
affected by antimicrobials and finally, altering the
permeability of their cell membrane making it difficult
for the antimicrobial to enter. Despite early uniform
susceptibility to penicillin, Staphylococcus acquired
penicillin-binding protein (PBP 2a), encoded by mecA
gene elaborating penicillinase that rendered penicillin
inactive and that is borne by nearly all the clinical
isolates(22). Methicillin resistance may also be associated
with mechanisms independent of mecA gene such as
hyper production of beta lactamase or methicillinases.
Most methicillin resistant Staphylococci are multi-
resistant, and the mec region may harbour several
resistance determinants resulting in a clustering of
resistance genes within this region(22). Penicillinase-
resistant beta-lactams such as methicillin were introduced
in 1960s but resistance to these has become an increasing
concern(2,3,13,22). In some developed countries, upto
60% of all hospital-acquired infections are due to
resistant bacteria and majority are caused by S. aureus(23).
Vancomycin, which is recommended in MRSA, is
usually not available in most developing countries.
STRATEGIES TO MINIMISE AND CONTROL
ANTIBIOTIC RESISTANCE IN S. AUREUS
Laboratory Services: Laboratory services are an
essential component of' curative and preventive health
care activities worldwide. Laboratory investigations are
a vital part of the clinical assessment and the results
det rmine selection of drugs for patient management.
In addition to confirmatory diagnosis, laboratory records
c nbe used for disease and drug surveillance.
The importance of surveillance of the antimicrobial
susceptibility pattern cannot be over emphasized as a
guide to the use of antimicrobial agents. Surveillance
will assist to define the extent of resistance among
different pathogens and in different populations, to
adjust treatment strategies and national drug policies
and to measure the success of intervention strategies.
In East African countries, laboratory services have been
established as part of the national health structure from
the central hospital through each level of health care
delivery to health centers and even dispensary level.
Primary Health Care (PHC) is first level of contact of
individuals with the health care system, and is accessible
to the majority of the rural population in developing
countries. In support of the primary health care strategies,
World Health Organization Laboratory Technology
programme adopted two major resolutions for the
African region; to develop appropriate technology for
health laboratories, and encourage member states to
dev lop health laboratory services(24). With currently
available facilities and manpower, health centers are
usually the smallest health units offering laboratory
services. Since they are usually situated in more
peripheral areas and are more numerous, health centers
provide the first line comprehensive diagnostic, curative
and preventive medical services for the majority of the
population. Unfortunately, these laboratories are far
from offering antibiotic sensitivity testing services.
Frequently, antibiotics (included in drug kit) are
prescribed and administered to patients without
laboratory diagnosis and determination of antibiotic
sensitivity patterns. Worse still, the administration of
antibiotics is often given to patients with viral or fungal
infections. Broad-spectrum antibiotics are frequently
given in place of specific ones to substitute for bacterial
identification and sensitivity testing. Intensive use of
antimicrobial agents for prophylaxis and treatment of
patients in hospitals make them a prime site for
emergence, maintenance and spread of resistant
pathogens(25). This may lead to drug wastage and
emerg nce of more resistant bacterial strains(26).
Prevention of emergence of antibiotic resistance during
treatment is therefore an important goal when prescribing
antimicrobials.
Problems affecting the operation of laboratories at
the peripheral level are widespread. These include lack
of properly designed laboratory rooms, unreliable access
to clean water or electrical power, shortage of equipment
and supplies, lack of effective equipment maintenance
services and little regular support supervision from
higher units(27). Consequently, the laboratories are
functioning below capacity. There is need for laboratory
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networking to the central or National Public Health
Reference Laboratory to support less developed/equipped
peripheral units that cannot even do culture and
sensitivity for surveillance activities. At the 7th Annual
Scientific Conference of the Kenya Association of
Clinical Pathologists in 1999, it was suggested that
there was need to improve laboratory services in health
facilities and reinforce strict regulations governing both
private and government laboratories.
In the East African countries, supplies for laboratory
services are put in the budget together with drugs and
medical supplies. Health authorities give priority to
treatment drugs when operating under severe economic
constraints. Furthermore, the impact of laboratory
services in improving diagnosis and rationalizing drug
use is not widely appreciated by medical personnel or
patients. National and international uthorities should
be encouraged to channel more resources into the
development of PHC laboratory services. However, the
long-term benefits of improved diagnosis are not
known, and the issues of cost reduction and whether
early diagnosis at outpatient level can reduce hospital
admissions are being addressed. Due to the increasing
prevalence of antimicrobial resistant S. aureus trains,
surveillance and effective treatment remain an important
tool for the management of infections caused by this
agent. Improved disease recognition improves the
accuracy of reporting and contributes to effective
national health planning(28). Co-operation and support
between countries on a regional and international basis,
together with patient education and demand for quality
services, are necessary to ensure widespread access to
essential laboratory services at primary health care level
in Africa.
National surveillance and monitoring programmes:
Although many factors may be able to influence
whether bacteria become insensitive to an antibiotic, the
two main forces are prevalence of resistance genes and
the extent of antibiotic use(20). There is no simple cure
for resistance, but opportunities for control lie in the
lesser and better use of antibiotics backed by swifter
and more accurate diagnosis and susceptibility testing,
developing new antibiotics and in protecting old ones
from developing resistance. All this must be supported
by good local knowledge of the epidemiology of
inflections and the likelihood of particular antibiotic
pressure to select resistance. The laboratory may serve
as a key surveillance point of information gathering and
dissemination for antimicrobial resistance data. For
instance, in the Netherlands (1989-1995), about 0.3%
of S. aureus isolates were resistant to methicillin and
non to vancomycin(29), while in Kenya, the prevalence
of methicillin resistant S. aureus was 39.8% but
addition of clavulonic acid to amoxycillin increased the
susceptibility three-fold(13). The low prevalence may
be due to restrictive use of antibiotics and to strict
isolation measures aimed at eradicating methicillin
resistant S. aureus. Methicillin resistance was particularly
associated with consumption of broadspectrum beta-
lactams, quinolones and total antibiotic consumption in
the ward. Thus antibiotic policy is an important factor
for limiting the emergence and spread of multiresistant
bacteria within the hospital environment(30). Currently,
most hospitals in developing countries do not have any
antibiotic policy. Hospitals should have a programme
for online antibiotic surveillance of drugs used in
v ri us units in order to change the empiric treatment
when there is an increase in antibiotic resistance. It is
also important o carry out a survey of antibiotic
consu ption in order to avoid further selective pressure
on bacteria showing increased resistance rates. To
prevent and control nosocomial infections, there is need
to increase national surveillance for infection rates so
that inter hospital comparisons are valid and work with
health care workers on better implementation of existing
control measures such as hand washing and physical
barrier nursing techniques. Critical factors that influence
any laboratory on monitoring antimicrobial resistance
include availability of high quality discs to measure
antibiotic sensitivity and participating in an active
quality control and proficiency testing programme to
ensure the validity of the results generated. Such a
network is not yet in place.
Nosocomial infections caused by S. aureus are as
a result of cross infection between patients and hospital
taff and tend to spread rapidly(8). Protective measures
for patients as well as staff must be applied and
maintained. The level of protection is high if disposable
produc s are used. Thus disposable materials to decrease
th incidence of nosocomial infections should replace
re-usables. In addition, hospital infection control
committees need to be set up and taken more seriously.
At Nairobi Hospital in Kenya, the problem of MRSA
was recognised in midyear of 1996 among both in and
out pati nts. Swift action by the hospital infection
control committee resulted in no more cases at the end
of the year(2). The national referral hospital (Kenyatta
National Hospital) also has a functional infection
control committee. These may serve as role models to
dis eminate information to smaller hospitals. As a step
forward, the Infection Control Association of Kenya
(ICAK) was launched in 1997 to coordinate infection
control countrywide and provide an effective
communication and networking channel between various
targ t and interested groups.
There is increasing concern regarding the efficacy
of many disinfectants on the market. MRSA was found
to be significantly less susceptible than methicilin
se sitive S. aureus (MSSA) to chlorhexidine digluconate,
'Hibiscrub' and 'Hibisol'. Hand disinfectants containing
both alcohol and chlohexidine ("Hibisol") are more
effective against MRSA than scrubs based only on
chlorhexidine (Hibiscrub') and should be used in clinical
practice(31). It is therefore important to select appropriate
concentration of disinfectant and rationally use them
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for disinfection and hospital hygiene. There is a
possibility that a significant proportion of laboratory or
hospital acquired infections may partly be due to the
use of ineffective or low concentration of disinfectants.
A continuous monitoring of the afficacy of the commonly
used disinfectants is necessary in order to minimise the
risk of infection by antibiotic resistant microorganisms,
which are common in the hospital.
Rational drug use policy development and
implementation: Programmes to improve rational and
effective drug use in developing countries are urgently
needed. In industrialised nations, most antibiotics are
available only on prescription, but this restriction does
not ensure proper use. Patients often fail to use the full
course of treatment, then stock pile the left over doses
and medicate themselves, or their family and friends
in less doses than therapeutic amounts. In these
circumstances, the improper dosing will fail to eliminate
the disease agent completely and exert a strong selective
pressure on the development of both chromosome and
plasmid mediated resistance, by destroying susceptible
bacteria in a population permitting resistant ones to
proliferate. This is a major factor limiting long-term
successful use of an antimicrobial agent, with infections
that were once easy to treat now proving quite
difficult(21). Unfortunately, when resistance becomes
a clinical problem, those countries that often do not
have access to expensive drugs may have no substitute
available.
In developing countries, antibiotic use is even less
controlled such that many antibiotics are available off
the counter(32,33). A study of antibiotic sale behavior
in retail chemist shops in Nairobi revealed that about
64% of chemists sell antibiotics without doctors
prescriptions, and most shops sold under dose drugs
according to the request of the patient(32). Surveys
need to be undertaken to determine the risk of dispensing
errors, factors contributing to the occurrence of
dispensing errors, the number of prescription items that
one pharmacist can safely dispense in a day. whether
countries should have a regulatory maximum dispensing
load and all estimation of the number of recent errors
at the pharmacist's work place. In Australia the principle
contributing factors were high prescription volumes,
pharmacists' fatigue, over work, interruptions to
dispensing and similar or confusing drug names(34).
In addition one of the factors necessary to improve the
risk of dispensing errors is to improve the doctors
handwritings. Dispensing errors are occurring in numbers
well above reports to regulatory authorities and seem
to be accepted as part of the practice. If drugs are to
retain their efficacy over pathogens, they have to be
used more responsibly. Standards need to be set
appropriately.
Antibacterial substances are used in considerable
amounts as growth promoters in animal husbandry and
for therapeutic purposes. There are however incalculable
risks for human health resulting from the use of
pa ticular feed additives(35). The application of
molecular methods to typing, and characterisation f
bacteria and their resistance genes has provided more
concise evidence for the transfer of antibiotic resistance
to glycopeptides and streptogramins among animals and
humans. In Kenya, a high frequency of antibiotic
resistance among S.aureus isolates from milk and meat
could be attributed to their use in treatment of disease
in animal husbandry(36). Contact with these animals
or consumption of flood products from them has been
the main route of dissemination of resistance to the
hum n population. This demonstrates how resistant
bacteria arising from indiscriminate use of antibiotics
in animals may impact on human health.
Problems of cost sharing in government health
facilities are enormous. Utilization of outpatient services
in government owned district hospitals in Dar-es-
Sala m declined by more than 50% following the
introduction of user charges in these health facilities
in mid July 1993(37). In such circumstances, patients
may resort to self-medication with consumption of
inadequate doses of antibiotics which result in low
levels of antibiotics  in the blood stream, a condition
conducive to the selection of resistance mutant(32).
This may be partly due to economic constraints coupled
with ongoing structural adjustments programmes faced
by the patients. Employees medical covers are almost
a thing of the past. Worse still the money levied on
patients is not necessarily used at the point of service.
For in tance, some countries have highlighted the need
to all w the laboratory service to retain most of the
funds from charges levied on laboratory tests as one
of the ways to sustain health laboratory services(28).
Clear policy guidelines on the rational use of antibiotics
need to be drawn up and reinforced(9).
Education (formal and informal)
Infection control Association of Kenya (ICAK) has
been vigorously promoting educational programmes in
the field of infection prevention and control for
pract tioners and health units countrywide in the form
of w kshops. Among key areas addressed are
establishing infection control units in hospitals,
emergence of drugs resistance and the role of antiseptics/
disinfectants in infection control.
In many developing countries people seek treatment
in pharmacy(38). Pharmacists usually fail to recognise
the infection and provide treatment most often with
ineffective regimens. Educational interventions and
improved couselling of patients for prevention is needed
to impr ve disease recognition, treatment and referral
practises. In Vietnam, the main reason for not taking
full course of antibiotics are not economic constraints,
but purchases' poor knowledge about antibiotics(33).
The study documents the need for better health education
about rational use of antibiotics in the general public.
In Kenya, most shops sold under-dose drugs according
578 EAST AFRICAN MEDICAL JOURNAL November 2002
to the request of the patient(32). Training shopkeppers
as a channel for information to the community is both
feasible and likely to have a big impact on behaviour
changes in malaria control and probably other infectious
diseases(39), including those that may be due to S.
aureus.
CONCLUSION
The epidemiology and antibiotic sensitivity of S.
aureus is changing worldwide. Although it is important
to search for newer and more effective antibiotics, it
is imperative that we develop a surgical mindset of
appropriate antibiotic stewardship(40). Tackling
antibiotics resistance require combined effort by the
health care providers and the patients at large. The
use of single dose prophylactic regimen, using narrow
spectrum agents when possible for therapeutic
indications, limiting the duration of therapeutic agents
appropriately, avoiding the use of vancomycin except
when necessary and the adhering to strict infection
control measures are all steps that will limit the spread
and development of resistance organisms. The existence
of a large reservoir genes in healthy individuals and
the environment in developing countries represents a
threat to the success of antimicrobial therapy. Antibiotic
resistance in developing countries needs to be monitored
closely. If drugs are to retain their efficacy over
pathogens, they must be used more responsibly especially
for those in developing countries where health budgets
are meager and the cost of newer drugs ever increasing.
Empirical treatment of infections in the absence of
susceptibility data is widely practised in health facilities.
It is important that collaborative national and
international studies on the incidence of antibiotic
resistance are performed on a repetitive basis. Thus
there is need for laboratory networking to cover the
whole country and international collaboration support
to health services. Results of such surveillance network
will allow for more economical and efficacious drugs
prescribing, and selection of essential drug list.
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